General Proximity Awarded $9 Million Grant from the Cancer Prevention and Research Institute of Texas (CPRIT) Recognizing the OmniTAC™ Induced Proximity Platform

On November 20, 2026 General Proximity, a biotechnology company discovering and developing the next generation of induced proximity medicines, reported it has been awarded a $9 million Product Development Research Program award from the Cancer Prevention and Research Institute of Texas (CPRIT) in the new technology category, recognizing General Proximity’s OmniTAC induced proximity platform. General Proximity was the only company awarded in this category.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Induced proximity medicines offer a differentiated approach: small molecules that bring two proteins into close physical proximity to induce a desired therapeutic effect, creating opportunities for traditionally undruggable targets.

The CPRIT award recognizes General Proximity’s proprietary OmniTAC platform, which enables unbiased screening for effector proteins capable of modulating disease-relevant targets. Many cancer drivers, including tumor suppressors that are lost or inactivated in tumors, have been considered undruggable because they cannot be addressed with conventional inhibitors. By systematically identifying effector proteins that can be brought into proximity with a target to modulate its function, OmniTAC opens a path to these targets. The award will fund General Proximity’s efforts to advance the OmniTAC-generated lead program into the clinic and to support the clinical validation of the platform.

"We are honored to receive this support from CPRIT, which underscores the potential of our OmniTAC platform and of induced proximity as a powerful new class of medicines," said Armand B. Cognetta III, PhD, Founder & Chief Executive Officer of General Proximity. "This award will help us move our lead program generated by OmniTAC into the clinic. We are also excited to expand our footprint in Texas and build relationships with Texas clinical sites and the state’s life sciences ecosystem."

CPRIT’s Product Development Research Program funds projects at Texas-based or relocating companies developing novel products or services intended to benefit cancer patients. CPRIT received 207 applications this year, 42 of them in the new technology category. CPRIT funded 12 applications in total, only one of which was in the new technology category.

(Press release, General Proximity, NOV 20, 2026, View Source [SID1234675044])